Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- spesolimab
- talimogene laherparepvec
Interactions between your drugs
talimogene laherparepvec spesolimab
Applies to: talimogene laherparepvec, spesolimab
CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.
MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Spevigo
Spevigo is used to treat generalized pustular psoriasis (GPP) in adults and children 12 years and ...
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Arcalyst
Arcalyst (rilonacept) is used to treat Cryopyrin-Associated Periodic Syndromes, Deficiency of ...
Bimzelx
Bimzelx (bimekizumab) treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and ...
Cinqair
Cinqair (reslizumab) is a monoclonal antibody that affects the actions of the body's immune system ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.